Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (monocyte progenitors) | 0.10 |
| chemistry Open Targets | compounds already reach it: gsk2816126, tazemetostat, tazemetostat hydrobromide | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 12 Parkinson's papers of 8,001 | 0.66 |
| pathways Reactome | 10 pathways; mostly iron and oxidative stress | 0.80 |
No case: the score is under the bar. Receipt 6889
Sealed predictions
- EZH2 in dopamine neurons, braak+0.28 (p 0.470) → +0.15 (p 0.705)receipt 6897
Swarm cases
receipt 6897: EZH2 in dopamine neurons, braak
- power
- full sample +0.24 (p 0.328, n 18), 95% CI -0.25 to +0.64. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.21 (p 0.398, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.23 (p 0.355, n 18). could be the mix.
- skeptic
- leave-one-out range +0.15 to +0.41, sign flips 0; without severely affected donors +0.24 (p 0.328, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for EZH2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts